Range Financial Group LLC Buys Shares of 21,452 Corcept Therapeutics Incorporated (NASDAQ:CORT)

Range Financial Group LLC purchased a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,452 shares of the biotechnology company’s stock, valued at approximately $1,081,000.

Several other large investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new position in Corcept Therapeutics in the 3rd quarter worth approximately $25,000. Kathleen S. Wright Associates Inc. bought a new position in shares of Corcept Therapeutics in the third quarter worth approximately $36,000. GAMMA Investing LLC increased its holdings in Corcept Therapeutics by 85.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,147 shares during the period. KBC Group NV raised its holdings in Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 496 shares in the last quarter. Finally, AA Financial Advisors LLC bought a new position in shares of Corcept Therapeutics in the 3rd quarter worth approximately $231,000. 93.61% of the stock is owned by institutional investors.

Insider Activity at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Guyer sold 6,606 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $48.97, for a total transaction of $323,495.82. Following the completion of the transaction, the insider now directly owns 5,796 shares of the company’s stock, valued at $283,830.12. The trade was a 53.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,811 shares of company stock valued at $1,840,080 over the last ninety days. 20.50% of the stock is owned by company insiders.

Corcept Therapeutics Trading Down 0.8 %

Shares of NASDAQ CORT traded down $0.41 during midday trading on Tuesday, hitting $51.25. The company’s stock had a trading volume of 625,311 shares, compared to its average volume of 771,836. The firm has a market cap of $5.37 billion, a P/E ratio of 40.67 and a beta of 0.56. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $62.22. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $54.63 and its two-hundred day moving average is $43.62.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $182.55 million for the quarter, compared to the consensus estimate of $171.97 million. During the same period last year, the business posted $0.28 EPS. Corcept Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. As a group, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

CORT has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday, October 31st. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Piper Sandler raised their price target on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Finally, Truist Financial boosted their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Corcept Therapeutics has an average rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.